Valerian Root Extract — Supplements
Europe's most commonly used herbal sleep aid with 2024 RCT evidence for sleep quality improvement; mechanism via GABA-A receptor modulation.
Overview
Valerian (Valeriana officinalis) has been used as a medicinal herb for sleep and anxiety since ancient Greece and Rome. It is the most commonly used herbal sleep preparation in Europe, particularly Germany (where it has official monograph status from the Commission E). A 2024 double-blind RCT in 80 adults with sleep complaints showed standardized valerian extract (2% valerenic acid) produced significant improvements in PSQI total score, sleep latency, total sleep time, and sleep efficiency at days 14, 28, and 56, with concurrent reduction in Beck Anxiety Inventory scores. However, a 2024 umbrella review in European Neuropsychopharmacology noted inconsistency in the overall literature, and the American Academy of Sleep Medicine (2017) recommends against valerian for chronic insomnia — a position reflecting methodological limitations of older trials rather than harm. Valerian's primary active constituent is valerenic acid, which inhibits GABA transaminase (the enzyme that degrades GABA), potentiates GABA-A receptor function, and acts as a partial agonist at adenosine A1 receptors. Unlike benzodiazepines, valerian does not produce tolerance, dependence, or next-day cognitive impairment at standard doses.
Indications
- Sleep onset insomnia and sleep quality improvement
- Restlessness, mild anxiety, and nervous tension
- Menopausal sleep disturbance
- Stress-related sleep disruption
Mechanism of Action
Valerenic acid inhibits GABA-T (gamma-aminobutyric acid transaminase), the enzyme responsible for GABA catabolism, increasing synaptic GABA concentrations in key sleep-regulatory circuits (VLPO, basal ganglia)
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Valerian root extract (standardized to 0.8% valerenic acids) | 300–600 mg | Once, 30-60 min before bed | Lower end (300 mg) for mild symptoms; 600 mg in acute sleep disturbance trials |
| Valerian root extract (2% valerenic acid) | 500 mg | Once daily before bed | Standardization used in 2024 RCT showing PSQI improvement; effect onset 2-4 weeks |
Safety & Contraindications
- Generally well tolerated; most common AEs: headache, dizziness, drowsiness, and GI discomfort (all comparable to placebo in most trials)
- Rare case reports of hepatotoxicity — unclear causal attribution; use cautious with hepatic disease and monitor LFTs if long-term use
- Abrupt discontinuation after prolonged high-dose use may cause withdrawal symptoms (restlessness, irritability) — taper gradually
- Possible additive CNS depression with alcohol, benzodiazepines, opioids — use caution
- May inhibit CYP3A4 in vitro — theoretical drug interaction at very high doses; clinical significance uncertain at standard doses
- Avoid in pregnancy and breastfeeding — insufficient safety data
- Product quality highly variable — valerenic acid content (active marker) varies widely between products; standardized extracts required